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Abstract 
Objective: In 2019, the European Society of Cardiology  led and released new guidelines for 
diabetes’ cardiovascular risk management, reflecting recent evidence of cardiovascular disease 
(CVD) reduction with sodium-glucose co-transporter-2 inhibitors (SGLT-2i) and some glucagon-
like peptide-1 receptor agonists (GLP1RA) in type 2 diabetes (T2D). A key recommendation is 
that all those with T2D who are (anti-hyperglycaemic) drug-naïve or on metformin 
monotherapy should be CVD-risk-stratified and an SGLT-2i or GLP1RA initiated in all those at 
high or very high risk, irrespective of glycated haemoglobin. We assessed the impact of these 
guidelines in Scotland were they introduced as is.  
Research Design and Methods: Using a nationwide diabetes register in Scotland, we did a cross-
sectional analysis, employing variables in our register for risk stratification at 1 January 2019. 
We were conservative in our definitions, assuming the absence of a risk factor where data were 
not available. The risk classifications were applied to those drug-naïve or metformin 
monotherapy people and the anticipated prescribing change calculated.  
Results: Of the 265,774 people with T2D in Scotland, 53,194 (20.0% of T2D) were drug-naïve 
and 56,906 (21.4%) were on metformin monotherapy. Of these, 74.5% and 72.4% respectively 
were estimated as at least high risk given the guideline risk definitions.  
Conclusion: Thus, 80,830 (30.4%) of all those with T2D (n=265,774) would start one of these 
drug classes according to table 7 and figure 3 of the guideline. The sizeable impact on drug 
budgets, enhanced clinical monitoring and the trade-off with reduced CVD-related healthcare 
costs will need careful consideration.  
 [247/250 words max] 
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Introduction 
Diabetes is a significant risk factor for cardiovascular disease (CVD).1 In recent years, new 
medicines have been licensed for the treatment of type 2 diabetes (T2D). In the case of sodium-
glucose co-transporter 2 inhibitors (SGLT-2i) and specific glucagon-like peptide-1 receptor 
agonists (GLP1RA), large cardiovascular and renal outcomes’ trials have variously 
demonstrated a lowering of the risk of future cardiovascular events, admissions due to heart 
failure (HF) and chronic kidney disease (CKD) progression as well as mortality postponement in 
people with T2D at elevated cardiovascular risk.2–8   
In August 2019, the European Society of Cardiology (ESC) in collaboration with the European 
Association for the Study of Diabetes (EASD) published new guidelines on ‘diabetes, pre-
diabetes and CVD’.9 These aimed to incorporate the beneficial effect on CVD of SGLT-2i and 
some GLP1RA in those with T2D into evidence-based guidelines but also align the management 
recommendations for T2D to a cardiovascular (CV) risk-stratified approach to initial treatment 
selection, rather like the modern management of other aspects of CV risk, particularly statins for 
hypercholesterolaemia. 
The ESC-led guideline (table 7 and figure 39) first divides people living with T2D into whether 
they are (anti-hyperglycaemic) drug-naïve or on metformin monotherapy, and then to one of 
three risk categories for CVD, depending on the presence or absence of features: very high, high 
and moderate risk (see table 1 for abbreviated description of these risk categories). Once 
assigned to being at high or very high risk, anyone currently drug-naïve or on metformin 
monotherapy is recommended to have a GLP1RA or an SGLT-2i with proven CV benefit2–8 
initiated, irrespective of baseline HbA1c or age (see table 2 for initial treatment algorithm 
modified from the guidelines)9.  
Although not currently adopted or endorsed in the United Kingdom (UK), Scotland or other 
countries, these guidelines are likely to influence clinical practice in many parts of Europe. In 
spite of the commendable aim of the ESC-led guidelines to reduce CVD in DM there is a 
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departure from convention in some aspects of the risk stratification and initial treatment 
selection for T2D. First, the disregarding of baseline HbA1c for initial treatment selection, when 
the trials had a minimum HbA1c in their inclusion criteria. Second, offering the agents to drug-
naïve people, when those included in the trials were on background treatment.  Third, and 
finally, issues around the tolerability and side effect profiles of these medicines such that they 
may be inappropriate for some or not adhered to.2–8  
In this study we explore the potential impact of strict adherence to specific sections (figure 3 
and table 7) of the guideline on new prescribing rates in the Scottish population of people with 
T2D through a main analysis and through a number of sensitivity analyses.  
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Method 
We did a cross-sectional analysis, applying table 7 and figure 3 of the ESC-led guideline9, using 
the Scottish Care Information (SCI)-Diabetes clinical information system. This includes >99% of 
those with a diagnosis of diabetes living in Scotland and records demographic information, 
prescriptions, routine clinical assessment (including retinal photographs), relevant laboratory 
measurements and, through linkage to routine administrative healthcare data (Scottish 
Morbidity Record 01(SMR01)), all hospital discharges. SCI-Diabetes has previously been 
described in detail.10,11  
We assessed eligibility for GLP1RA and SGLT-2i in all those alive and observable (an active 
patient, based on recent evidence of laboratory results, prescribing, screening or hospital 
admission data) with T2D and either drug-naïve or on metformin monotherapy as of 1 January 
2019 (our latest data extract).  
CV risk, in accordance with the ESC-led guideline, was evaluated from clinical history and 
laboratory data in SCI-Diabetes, linked to prior hospitalisations for CVD in SMR01. We were 
conservative in our allocation of definitions, assuming the absence of risk factor where data 
were not available. We used the following definitions: we defined “established atherosclerotic 
CVD” (ASCVD) as prior hospital discharge that included any cardiovascular, cerebrovascular or 
peripheral vascular ICD-10 code (see supplementary table S1). For target organ damage, the 
definitions in the ESC-led guidelines are: proteinuria, renal impairment (estimated glomerular 
filtration rate (eGFR) < 30 mL/min/1.73 m2), left ventricular hypertrophy (LVH) or retinopathy. 
The guideline does not give a precise definition of proteinuria, so we counted all people with 
micro- and macroalbuminuria (albumin-creatinine ratio >3.39 mg/mmol (>30 mg/g)) as 
proteinuric, as would be conventional.12 Other than ‘LVH hospital discharges’, which met the 
criterion for established ASCVD, LVH could not be captured (so our definition of target organ 
damage is potentially conservative in this respect). The guideline does not define retinopathy, 
so we used a conservative definition of having a retinopathy screening grade of moderate non-
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proliferative/moderate pre-proliferative or worse retinopathy or referable maculopathy (the 
criterion for referral to an eye clinic in our screening programme).  
The guideline specifies that the risk factors that should be considered are: age, hypertension, 
dyslipidaemia, smoking and obesity, but does not actually define what thresholds of these to 
use. Therefore we used the following cut-offs to define presence of the risk factor: age ≥65 
years; a systolic blood pressure (SBP) ≥135 mmHg or treated hypertension; a low-density 
lipoprotein – cholesterol (LDL-C) ≥2.5mmol/L or total cholesterol (TC) ≥4.5mmol/L; current 
smoking; or a body mass index ≥30kg/m2. Diabetes duration was based on date of diagnosis and 
verified against prescribing data, presence of diabetes codes on hospital discharge data and 
HbA1c data. Drug prescribing records were then utilised to define whether individuals were 
T2D drug-naïve or on metformin monotherapy and to define the current level of exposure to 
SGLT-2i and GLP1RA. Like the algorithm used in the guidelines, we treated drug-naïve and 
metformin monotherapy individuals separately (but also calculated the risk strata in the whole 
population for reference) and then assigned people to having i) moderate, ii) high or iii) very 
high risk of CVD. Table 3 describes the distribution of the various characteristics in the whole 
Scottish population with T2D and also in drug-naïve and metformin monotherapy people.  
In light of the definitions of i) some forms of target organ damage and ii) the cut-offs for risk 
factor definitions being arbitrarily defined, we did sensitivity analyses by modifying our 
definitions of these to see how this changed the classification of people to risk categories and 
hence eligibility. We also did sensitivity analyses using different minimum thresholds of HbA1c 
for prescribing to examine how this changed eligibility for these medicines, as although ESC-led 
guidelines do not recommend consideration of these for eligibility, current prescribing 
guidelines in the UK and Scotland do. We also investigated the effect of setting an upper age 
limit for eligibility to see how this affects numbers eligible. Of note the risk algorithm in the 
guidelines is based on the presence or absence of ASCVD, organ damage and risk factors but not 
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HbA1c and age (which is considered a risk factor as a binary variable ≥65y but not an eligibility 
criteria) (all sensitivity analyses in table S2). 
We deliberately did not undertake a cost-effectiveness analysis of this guideline given the 
multiple agents with different risk/benefit profiles being examined, as well as varying costs 
between countries. Our focus was the first component of the treatment algorithm (figure 3, page 
31 of the guidelines), as the other downstream components are conditional statements based on 
initial treatment response, assessed by HbA1c, which cannot be known.9  
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Results 
265,774 people were alive and observable with T2D in Scotland on 1 January 2019. Of these, 
53,194 (20.0%) were drug-naïve and 56,906 (21.4%) were on metformin monotherapy.  
Applying even our conservative risk stratification criteria to the whole population with T2D, 
188,367 (70.9%) people were identified as being at very high risk of CVD and a further 25,957 
(9.8%) were identified as being at high risk. The guideline states that simply having a diagnosis 
of T2D puts people at moderate CVD risk, so the remainder were classified as such (n=51,450, 
19.4%).9 In this population of people with T2D in Scotland, of those classified as very high risk, 
90,396 (48.0%) had established ASCVD; 72,765 (38.6%) had target organ damage; and 138,010 
(73.3%) had ≥3 major risk factors. Presence of any one of these features was sufficient to be 
classified as very high risk (see table 2) and some people have >1 of these. 115,756 (43.6% of all 
people with T2D) people had “diabetes duration >10 years (y) and least one additional risk 
factor”, the criteria for high risk. Of these, 89,799 also met the very high risk criteria such that 
25,957 were classified as high risk only.  
Table 3 describes the differences between the entire population with T2D and those who are 
drug-naïve and on metformin monotherapy. Compared to the whole T2D population, the drug-
naïve or on metformin monotherapy groups had fewer people with prevalent ASCVD, fewer 
people with organ damage and fewer people with a diabetes duration >10y. The drug-naïve and 
metformin monotherapy groups had similar levels of hypertension and smoking prevalence but 
the drug-naïve group was older (71.0y (interquartile range (IQR) 61.8, 79.3) vs 66.4y (IQR 57.1, 
74.7), with fewer obese people (50.2% vs. 56.0%) and had more dyslipidaemia (47.9% vs 
40.3%). The median HbA1c was lower in the drug-naïve than the metformin monotherapy 
group, 47mmol/mol ((IQR 42, 52) (6.5% (IQR 6.0%, 6.9%)) vs 53mmol/mol (IQR 47, 61) (7.0% 
(IQR 6.5%, 7.7%)), and also a lower prevalence of those with an HbA1c ≥53 mmol/mol (≥7%) 
(23.3% vs 51.5%).13,14 In table 3, we also show the levels of exposure to drugs which affect CVD 
risk (all cardiovascular drugs, anti-hypertensives, anti-platelets, anti-coagulants and cholesterol 
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lowering drugs) in the groups. Most drug-naïve and metformin monotherapy people already 
have high levels of exposure to drugs that prevent CVD.  
Of the 53,194 people who were drug-naïve, 4.0% were considered high risk and 70.5% very 
high risk. Of the 56,906 people on metformin monotherapy 6.5% were considered high risk and 
65.9% very high risk. Drug-naïve people also had a higher prevalence of ASCVD (33.2% vs. 30.3) 
and ≥3 major risk factors (57.1% vs. 51.2%) which accounts for the differences in high risk and 
very high-risk proportions (see figure 1 for risk-stratification break down). 
Thus 74.5% (n=39,630/53,194) of drug-naïve individuals and 72.4% (n=41,200/56,906) of 
people on metformin monotherapy (see figure 2) would be eligible to receive an SGLT-2i or 
GLP1RA (n= 80,830 beyond current prescribing levels of n=31,228 of people currently exposed 
to SGLT-2i and/or GLP1RA in Scotland). In other words, this would mean initiation of either an 
SGLT-2i or a GLP1RA in almost one third (30.4% 80,830/265,774) of people with T2D were this 
guideline implemented as is. Whilst during 2019 number of people exposed will likely have 
increased, most of this increase is expected to have occurred in those with T2D previously on ≥1 
drug, given the current guideline recommendations.13,14  
In our sensitivity analyses we examined lowering or raising, where appropriate, the threshold 
for classification of a variable not precisely defined by the guidelines, while holding the 
remaining variable thresholds as described above. None of the sensitivity analyses changed the 
total eligible population by >±6%. The greatest decrease in eligibility occurred by increasing the 
limit of the age risk factor to ≥70y (c.f. ≥65y), resulting in 4,108 (-5.1%) fewer people being 
eligible for an SGLT-2i or GLP1RA. The greatest increase in eligibility came by lowering the 
threshold of the dyslipidaemia risk factor total cholesterol component to ≥4.0mmol/L (c.f. 
≥4.5mmol/L), leading to 4,794 (+5.9%) more people being eligible for drug therapy.  
We did further sensitivity analysis exploring the effect of setting an HbA1c threshold for 
prescribing eligibility. In this instance, those eligible for treatment fell with an increasing HbA1c 
threshold for prescribing (-45.1% (n=-38,602) from baseline analysis at >48mmol/mol (>6.5%) 
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threshold to -80.0% (n=-66,813) at >58mmol/mol (>7.5%) threshold). We also examined the 
effect of setting an upper age limit for prescribing eligibility to the baseline analysis where 
eligibility increased with an increasing age threshold (-21.1% (n=-19,255) from baseline at 
≥80y to -3.06% (n=-4,644) from baseline at ≥90y). Neither the HbA1c or age threshold are part 
of the risk stratification or initial therapy selection criteria in the guideline. 
All sensitivity analyses are reported in table S2.  
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Discussion  
In this conservative analysis of strict application of the ESC-led risk stratification tool to people 
with T2D who were drug-naïve or on metformin monotherapy, >30% of the entire population of 
those with T2D would immediately become eligible to receive an SGLT-2i or GLP1RA on the 
basis of CV risk stratification in our baseline analysis. Current guidelines in the UK and Scotland 
recommend SGLT-2i as second or subsequent-line therapy and GLP1RA as third or subsequent-
line therapy on the basis of failure to achieve pre-specified HbA1c targets (although the 
guidelines do make allowance for earlier introduction in contemplation of pre-existing CVD).13,14  
74.5% of drug-naïve and 72.4% of people on metformin monotherapy would be eligible to 
receive these new classes of drugs straight away on the basis of the guidelines (where 4.0% and 
6.5% were considered high risk and 70.5% and 65.9% were considered at very high risk, 
respectively), a large majority. This pattern of risk classification holds in the overall Scottish 
population of people living with T2D (including those who are not drug-naïve or on metformin 
monotherapy) where the majority of people (70.9%) would be considered very high risk with a 
smaller proportion considered high risk (9.8%).  
Our findings remained stable in sensitivity analysis (<±6% shift in eligibility for drug-naïve 
people and those on metformin monotherapy for every not-precisely-defined variable changed), 
mainly because this exercise resulted in people shifting between high risk and very high risk 
categories, with both groups being eligible for the new classes of medicines, and not between 
very high/high risk and moderate risk, which would have reduced eligibility. However, were a 
minimum target HbA1c threshold for prescribing introduced this would lead to a significant 
decrease in eligibility for these drugs from baseline from -45.1% to -77.8% from baseline analysis 
(at >48mmol/mol (>6.5%) vs. >58mmol/mol (>7.5%)). If an age-related prescribing threshold 
were set, this would also reduce eligibility from baseline more modestly than an HbA1c 
threshold, from -21.0% to -3.06% from baseline (at age >80 vs. age >90), with the reduction 
attenuating with increasing age.  
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Whether our findings of an overwhelming increase in immediate eligibility of SGLT-2i and 
GLP1RA prescribing by applying the ESC-led guidelines generalise to other countries remains to 
be seen. In Scotland we found 38.0% of the population living with T2D have prevalent ASCVD 
and a recent (2017) systematic review of the literature reported a prevalence of ASCVD in T2D 
of 32.2% worldwide (Europe = 30.0%, North America and Caribbean = 46.0%, South East Asia = 
42.5%, South and Central America = 27.5%, Western Pacific (including China) = 33.6 and Middle 
East and North Africa = 26.9%).15 Thus our analysis may over- or underestimate the level of 
eligibility to these newer classes of drugs depending on region. The proportion of drug-naïve 
people with T2D in Sweden was found to be 37.9% (2015)16 and 38.5% for those on metformin 
monotherapy (2012)17 (compared with 20.0% and 21.4% in Scotland respectively). Although 
these proportions are likely to have decreased somewhat in the intervening years, given the 
increased push for earlier and more intense treatment for T2D in guidelines, these numbers 
suggest that the proportion of people eligible for immediate initiation of an SGLT-2i or GLP1RA 
under the 2019 ESC-led guidelines are likely to be broadly similar in most other European 
countries. As a rough calculation, taking the NICE per person per annum (p.a.) costings for the 
cheapest SGLT-2i (canagliflozin at £477.26 p.a.) given to all 80,830 people eligible, this would 
cost ~£38.6 million in Scotland.18 
The strengths of this study include extensive data we hold for an entire population with T2D 
and a large sample size with almost complete capture of variables (with the exception of 
echocardiographic values for LVH).  
The limitations are that some of the definitions of risk factors are arbitrary (although we have 
attempted to use conservative working definitions). It is also unclear whether the 
discriminatory ability of the ESC-led risk stratification system has been validated and whether it 
truly identifies those who benefit most from treatment with an SGLT-2i or a GLP1RA or results 
in over estimation of CV risk and consequently overprescribing, particularly in light of more 
complex risk assessment tools recently being shown to over-estimate CV risk in T2D.19,20 The 
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guidelines’ algorithm for risk stratification might, indeed,  be considered crude in light of more 
refined cardiovascular risk engines for T2D becoming available.20 Whether it is possible to have 
specific risk scores that includes risk for major adverse cardiovascular events, and HF, should 
also be urgently investigated. 
We did not perform a cost-effectiveness analysis due to the number of agents considered by the 
guidelines (at least 4) and thus do not provide the estimated cost benefit of CVD/CKD risk 
reduction, mortality postponement and reduced hospitalisation, another limitation to the study. 
This is because our paper’s main focus is the magnitude of prescribing change however a formal 
cost-benefit analysis should be undertaken in due course and we hope that our data will inform 
this. Also this analysis would have to take into consideration modelling accounting the 
prescribing of SGLT-2i/GLP1RA which would occur beyond initial treatment selection in the 
algorithm based on the conditional statements of not achieving an HbA1c target, which we did 
not attempt to do. However the order of magnitude of the expected reduction in major adverse 
cardiovascular events can be gleaned from the hazard ratios of the cardiovascular outcomes’ 
trials: liraglutide, 0.87 (95% confidence interval (CI) 0.78, 0.97)5, semaglutide 0.74 (95% CI 
0.58, 0.95)6, empagliflozin 0.86 (95% CI 0.74, 0.99)4 and canagliflozin 0.86, (95% CI 0.75, 0.97)3. 
In addition, it remains to be seen if ignoring glycaemic control for initial therapy selection is 
advised in future national guidelines. This is because those with acceptable glycaemic control 
(typically HbA1c ≤53mmol/mol (≤7%)) were not eligible for outcomes’ trial participation. Thus 
it is unclear whether the benefits observed extend to these people.2–8  However given recent 
trial evidence, the American Diabetes Association (ADA) and the EASD have recently issued a 
brief update to their ‘management of hyperglycaemia in [T2D], 2018’ guidelines.21 This states 
“in appropriate high risk individuals with established [T2D], the decision to treat with a 
[GLP1RA] or an [SGLT-2i] to reduce [CV and CKD] outcomes should be considered 
independently of baseline HbA1c or individualised HbA1c target”.22  In brief, recently published 
outcomes’ trials for i) dulaglutide showed equivalent efficacy both above and below the median 
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HbA1c of 56 mmol/mol (7.3%) and had no lower minimum HbA1c for enrolment7 and ii) 
dapagliflozin in HF showed a reduction in HF and CV mortality outcomes in people both with 
and without diabetes.23 On this basis, it appears that the beneficial effects of these medicines 
may indeed be independent of glycaemia, so disregarding baseline HbA1c for eligibility for these 
classes of drugs is likely to become more commonplace in the future. It will be interesting to see 
if the step change is incorporated into ADA Standards of Medical Care in Diabetes. However, 
since the main focus of the current ADA/EASD consensus statement remains achieving an 
individualised HbA1c target rather than choosing initial therapy based on CVD risk (which is the 
major difference in the ESC-led guidelines), our sensitivity analysis of HbA1c thresholds implies 
that there would be much less new prescribing under the current ADA/EASD consensus than 
under the ESC-led guidelines.21 Furthermore, the outcomes’ trials included people who were 
already on background anti-hyperglycaemic therapy (usually at least metformin), so whether 
the same CV advantage is seen in drug-naïve people is unclear. The guideline justifies this by 
stating “The results obtained from these trials, using both GLP1RAs… and SGLT2 inhibitors…, 
strongly suggest that these drugs should be recommended in patients with T2D with prevalent 
CVD or very high/high CV risk, such as those with target-organ damage or several 
[cardiovascular risk factors], whether they are treatment-naïve or already on metformin.” It also 
suggests than an SGLT-2i is of particular benefit in people who exhibit “a high risk for HF”, 
although the guideline’s risk stratification tool does not appear to discriminate for this.9 
There are known harms associated with these medicines, such as genitourinary infections and 
diabetic ketoacidosis with SGLT-2i, and gastrointestinal adverse effects and potential worsening 
of retinopathy with GLP1RA.2–8 It is unclear whether it is possible to identify those at greatest 
risk of harm and, indeed, whether the adverse effect profiles of these medicines are tolerable 
such that those eligible would adhere with treatment, if offered. Also, the acceptability of 
injectable therapies (i.e. GLP-1RA), given the training, discomfort and inconvenience, is 
uncertain. There are also questions about whether these therapies are appropriate for the very 
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old or the frail, especially if added to an already extensive medication burden, although setting 
an age limit of 80y for prescribing only reduced eligibility by ~20% from baseline.  
For the first time in the management of T2D, drug therapies that not only improve glycaemic 
control but reduce risk of CVD, HF and CKD, and improve survival, are available. These new ESC-
led guidelines for the management of diabetes are clearly a step change in prescribing 
recommendations for the management of T2D incorporating, as they do, the evidence of 
cardiovascular benefit of SGLT-2i and GLP1RA. Such benefits are independent of glycaemia 
change. However, there are also controversial aspects to the guideline, which brings the 
management of T2D in line with others that incorporate a risk-stratified approach to the 
selection of initial therapy (like the risk-stratified approach recommended for the offering of 
statin therapy in some guidelines).  
Nevertheless, a detailed health economic assessment needs to be made, balancing the costs of 
offering these new medicines compared to cost-savings brought about by the expected 
reduction in CV/HF/CKD events. Furthermore, there could be shorter-term benefits on blood 
pressure and weight so that it is currently difficult to establish the cost-effectiveness of these 
new guidelines. The costs related to the known harms associated with these medicines would 
also need to be taken into account, as would the monitoring for harms or training for injectable 
therapy.  
In short, evidence exists for the benefits of SGLT-2i and GLP1RA with proven CV benefit in T2D, 
especially in those at elevated cardiovascular, renovascular or HF risk. We believe that policy 
makers will find our analysis useful when considering whether, or how, to apply the 
recommendations in the ESC-led 2019 guidelines on ‘diabetes, pre-diabetes and CVD’. More 
importantly, we hope our work can help improve future iterations of such guidelines.  
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Table 1. Risk category definition modified from table 7 in the guideline9, references to type 1 diabetes removed.  
Risk category Characteristics 
Very high risk Patients with diabetes mellitus (DM) and 
established CVD 
 or other target organ damage;  
 or three or more major risk factors 
High risk Patients with DM duration ≥10 years without 
target organ damage plus any other 
additional risk factor 
Moderate risk Young patients (T2D) aged <50 years) with 
DM duration <10 years, without other risk 
factors [everyone with T2D considered at 
moderate risk] 
Definitions  
Target organ damage Proteinuria, renal impairment defined as 
eGFR <30 mL/min/1.73 m2, left ventricular 
hypertrophy, or retinopathy 
Major risk factors Age, hypertension, dyslipidaemia, smoking, 
obesity 
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Table 2. Initial therapy selection only, modified from figure 3 of the guideline9   
T2D – Anti-hyperglycaemic drug-naïve T2D - On metformin monotherapy 
↓ ↓ 
Atherosclerotic cardiovascular disease or 
high / very high CV risk (target organ damage 
or multiple risk factors) 
Atherosclerotic cardiovascular disease or 
high / very high CV risk (target organ damage 
or multiple risk factors) 
Present                                Absent  Present                               Absent 
      ↓                                              ↓         ↓                                          ↓ 
SGLT-2i or GLP1RA         Metformin  
monotherapy                    monotherapy 
Add SGLT-2i.                  Continue Metformin 
or GLP1RA                      Monotherapy   
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Table 3, overall distribution of population characteristics contributing to risk stratification 
Characteristics contributing to 
risk stratification 
Total T2D 
population  
N (%) 
Drug-naïve 
population 
N (%) 
Metformin 
monotherapy 
population 
N (%) 
T2D (denominator) 265,774 (100.0) 53,194 (100.0) 56,906 (100.0) 
ASCVD 100,888 (38.0) 17,667 (33.2) 17,218 (30.3) 
Target organ damage (any) 72,765 (27.4) 8,802 (16.6) 10,645 (18.7) 
Proteinuria 60,660 (22.8) 7,892 (14.8) 9,548 (16.8) 
Renal impairment (eGFR < 
30 mL/min/1.73 m2) 
8,395 (3.16) 1,015 (1.91) 300 (0.53) 
LVH NA (NA) NA (NA) NA (NA) 
Retinopathy 16,018 (6.03) 578 (1.09) 1,221 (2.15) 
Diabetes duration >10 years 117,054 (44.0) 8,947 (16.8) 13,404 (23.6) 
Major risk factor    
Age ≥65y 156,294 (58.8) 35,786 (67.3) 30,691 (53.9) 
Hypertension 222,738 (83.8) 44,799 (84.2) 47,371 (83.2) 
Dyslipidaemia 106,391 (40.0) 25,498 (47.9) 22,956 (40.3) 
Smoking 41,107 (15.5) 7,566 (14.2) 9,920 (17.4) 
Obesity 144,171 (54.3) 26,708 (50.2) 31,843 (56.0) 
≥3 major risk factorsa 138,010 (51.9) 30,392 (57.1) 29,109 (51.2) 
Diabetes duration >10 years + any 
other additional risk factorb 
115,756 (43.6) 8,912 (16.8) 13,275 (23.3) 
Characteristics not contributing to 
risk stratification 
   
Age years median (IQR)c 68.1 (58.7, 76.5) 
 
71.0 (61.8, 79.3) 66.4 (57.1, 74.7) 
HbA1c mmol/mol median (IQR)  55 (47, 67) 47 (42, 52) 53 (47, 61) 
(HbA1c % (IQR))c (7.2 (6.4, 8.3)) (6.5 (6.0, 6.9))  (7.0 (6.5, 7.7)) 
HbA1c ≥53 mmol/mol (≥7%)c 151,708 (57.1) 12,373 (23.26) 29,314 (51.5) 
All cardiovascular drugs c, d 232,623 (87.5) 45,109 (84.8) 50,669 (89.0) 
Lipid modifying agents c, d 185,241 (69.7) 32,887 (61.8) 41,370 (72.7) 
Anti-platelet agents c, d 83,230 (31.3) 15,044 (28.3) 16,042 (28.1) 
Anti-hypertensives c, d 195,291 (73.5) 39,082 (73.5) 41,451 (72.8) 
Anti-coagulants c, d   23,665 (8.90) 5,500 (10.3) 4,328 (7.61) 
a = all classified as ‘very high risk’. 
b = criteria for ‘high risk’, note that some people counted here may be classified as very high risk 
due to the presence of additional risk factors, target organ damage or presence of ASCVD see 
table 1 for each risk band.  
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c = not used in risk stratification but given for reference.  
d = see supplementary table S3 for ATC codes of drugs in these classes  
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Figure 1, risk stratification of drug-naïve and metformin monotherapy population
27 
 
Figure 2, risk stratification of only drug-naïve and metformin monotherapy population with type 2 diabetes 
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Supplementary Table S1 ICD codes for ASCVD and N people 
icd.code N description 
G45.0 86 Vertebro-basilar artery syndrome 
G45.1 85 Carotid artery syndrome (hemispheric) 
G45.2 2 Multiple and bilateral precerebral artery syndromes 
G45.3 219 Amaurosis fugax 
G45.4 104 Transient global amnesia 
G45.8 226 Other transient cerebral ischaemic attacks and related syndromes 
G45.9 6651 Transient cerebral ischaemic attack, unspecified 
G46.0 20 Middle cerebral artery syndrome 
G46.1 63 Anterior cerebral artery syndrome 
G46.2 67 Posterior cerebral artery syndrome 
G46.3 21 Brain stem stroke syndrome 
G46.4 29 Cerebellar stroke syndrome 
G46.5 25 Pure motor lacunar syndrome 
G46.7 264 Other lacunar syndromes 
G46.8 9 Other vascular syndromes of brain in cerebrovascular diseases 
I11.0 215 Hypertensive heart disease with (congestive) heart failure 
I11.00 27 Hypertensive heart disease with (congestive) heart failure -- Reduced Left 
Ventricular Ejection Fraction (ISD Extension) 
I11.01 16 Hypertensive heart disease with (congestive) heart failure -- Preserved Left 
Ventricular Ejection Fraction (ISD Extension) 
I11.09 41 Hypertensive heart disease with (congestive) heart failure -- No information 
on Left Ventricular Ejection Fraction (ISD Extension) 
I11.9 375 Hypertensive heart disease without (congestive) heart failure 
I13.0 6 Hypertensive heart and renal disease with (congestive) heart failure 
I13.00 1 Hypertensive heart and renal disease with (congestive) heart failure -- 
Reduced Left Ventricular Ejection Fraction (ISD Extension) 
I13.09 1 Hypertensive heart and renal disease with (congestive) heart failure -- No 
information on Left Ventricular Ejection Fraction (ISD Extension) 
I13.1 10 Hypertensive heart and renal disease with renal failure 
I13.2 11 Hypertensive heart and renal disease with both (congestive) heart failure 
and renal failure 
I13.21 3 Hypertensive heart and renal disease with both (congestive) heart failure 
and renal failure -- Preserved Left Ventricular Ejection Fraction (ISD 
Extension) 
I13.9 28 Hypertensive heart and renal disease, unspecified 
I20.0 1403
4 
Unstable angina 
I20.00 889 Unstable angina -- Clinical statement - 'troponin positive' - (THIS EXTENSION 
NOW OBSOLETE) (ISD Extension) 
I20.01 1391 Unstable angina -- Clinical statement - 'troponin negative' - (THIS EXTENSION 
NOW OBSOLETE) (ISD Extension) 
I20.02 365 Unstable angina -- Coder knows troponin was measured but has no clinical 
statement of 'troponin positive' or 'troponin negative - (THIS EXTENSION 
NOW OBSOLETE) (ISD Extension) 
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I20.09 775 Unstable angina -- Coder does not know if troponin was measure OR coder 
knows troponin not measured - (THIS EXTENSION NOW OBSOLETE) (ISD 
Extension) 
I20.1 418 Angina pectoris with documented spasm 
I20.8 2814 Other forms of angina pectoris 
I20.9 6716
4 
Angina pectoris, unspecified 
I21.0 3879 Acute transmural myocardial infarction of anterior wall 
I21.00 1236 Acute transmural myocardial infarction of anterior wall -- Non-ST Elevated 
Myocardial Infarction (NSTEMI) (ISD Extension) 
I21.01 2382 Acute transmural myocardial infarction of anterior wall -- ST Elevated 
Myocardial Infarction (STEMI) (ISD Extension) 
I21.09 265 Acute transmural myocardial infarction of anterior wall -- MI with no 
statement of ST elevation or non-elevation (ISD Extension) 
I21.1 6167 Acute transmural myocardial infarction of inferior wall 
I21.10 810 Acute transmural myocardial infarction of inferior wall -- Non-ST Elevated 
Myocardial Infarction (NSTEMI) (ISD Extension) 
I21.11 3454 Acute transmural myocardial infarction of inferior wall -- ST Elevated 
Myocardial Infarction (STEMI) (ISD Extension) 
I21.19 272 Acute transmural myocardial infarction of inferior wall -- MI with no 
statement of ST elevation or non-elevation (ISD Extension) 
I21.2 560 Acute transmural myocardial infarction of other sites 
I21.20 165 Acute transmural myocardial infarction of other sites -- Non-ST Elevated 
Myocardial Infarction (NSTEMI) (ISD Extension) 
I21.21 304 Acute transmural myocardial infarction of other sites -- ST Elevated 
Myocardial Infarction (STEMI) (ISD Extension) 
I21.29 62 Acute transmural myocardial infarction of other sites -- MI with no 
statement of ST elevation or non-elevation (ISD Extension) 
I21.3 223 Acute transmural myocardial infarction of unspecified site 
I21.30 473 Acute transmural myocardial infarction of unspecified site -- Non-ST Elevated 
Myocardial Infarction (NSTEMI) (ISD Extension) 
I21.31 36 Acute transmural myocardial infarction of unspecified site -- ST Elevated 
Myocardial Infarction (STEMI) (ISD Extension) 
I21.39 69 Acute transmural myocardial infarction of unspecified site -- MI with no 
statement of ST elevation or non-elevation (ISD Extension) 
I21.4 3384 Acute subendocardial myocardial infarction 
I21.40 306 Acute subendocardial myocardial infarction -- Non-ST Elevated Myocardial 
Infarction (NSTEMI) (ISD Extension) 
I21.41 16 Acute subendocardial myocardial infarction -- ST Elevated Myocardial 
Infarction (STEMI) (ISD Extension) 
I21.49 24 Acute subendocardial myocardial infarction -- MI with no statement of ST 
elevation or non-elevation (ISD Extension) 
I21.9 7163 Acute myocardial infarction, unspecified 
I21.90 1662
7 
Acute myocardial infarction, unspecified -- Non-ST Elevated Myocardial 
Infarction (NSTEMI) (ISD Extension) 
I21.91 1100 Acute myocardial infarction, unspecified -- ST Elevated Myocardial Infarction 
(STEMI) (ISD Extension) 
I21.99 1120 Acute myocardial infarction, unspecified -- MI with no statement of ST 
elevation or non-elevation (ISD Extension) 
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I22.0 218 Subsequent myocardial infarction of anterior wall 
I22.00 30 Subsequent myocardial infarction of anterior wall -- Non-ST Elevated 
Myocardial Infarction (NSTEMI) (ISD Extension) 
I22.01 36 Subsequent myocardial infarction of anterior wall -- ST Elevated Myocardial 
Infarction (STEMI) (ISD Extension) 
I22.09 10 Subsequent myocardial infarction of anterior wall -- MI with no statement of 
ST elevation or non-elevation (ISD Extension) 
I22.1 428 Subsequent myocardial infarction of inferior wall 
I22.10 28 Subsequent myocardial infarction of inferior wall -- Non-ST Elevated 
Myocardial Infarction (NSTEMI) (ISD Extension) 
I22.11 92 Subsequent myocardial infarction of inferior wall -- ST Elevated Myocardial 
Infarction (STEMI) (ISD Extension) 
I22.19 2 Subsequent myocardial infarction of inferior wall -- MI with no statement of 
ST elevation or non-elevation (ISD Extension) 
I22.8 483 Subsequent myocardial infarction of other sites 
I22.80 77 Subsequent myocardial infarction of other sites -- Non-ST Elevated 
Myocardial Infarction (NSTEMI) (ISD Extension) 
I22.81 9 Subsequent myocardial infarction of other sites -- ST Elevated Myocardial 
Infarction (STEMI) (ISD Extension) 
I22.89 5 Subsequent myocardial infarction of other sites -- MI with no statement of 
ST elevation or non-elevation (ISD Extension) 
I22.9 548 Subsequent myocardial infarction of unspecified site 
I22.90 643 Subsequent myocardial infarction of unspecified site -- Non-ST Elevated 
Myocardial Infarction (NSTEMI) (ISD Extension) 
I22.91 22 Subsequent myocardial infarction of unspecified site -- ST Elevated 
Myocardial Infarction (STEMI) (ISD Extension) 
I22.99 31 Subsequent myocardial infarction of unspecified site -- MI with no statement 
of ST elevation or non-elevation (ISD Extension) 
I23.1 14 Atrial septal defect as current complication following acute myocardial 
infarction 
I23.2 42 Ventricular septal defect as current complication following acute myocardial 
infarction 
I23.4 1 Rupture of chordae tendineae as current complication following acute 
myocardial infarction 
I23.5 7 Rupture of papillary muscle as current complication following acute 
myocardial infarction 
I23.6 9 Thrombosis of atrium, auricular appendage, and ventricle as current 
complications following acute myocardial infarction 
I23.8 29 Other current complications following acute myocardial infarction 
I24.0 1020 Coronary thrombosis not resulting in myocardial infarction 
I24.1 58 Dressler syndrome 
I24.8 2912 Other forms of acute ischaemic heart disease 
I24.9 1218 Acute ischaemic heart disease, unspecified 
I25.0 250 Atherosclerotic cardiovascular disease, so described 
I25.1 9414
3 
Atherosclerotic heart disease 
I25.2 6448
5 
Old myocardial infarction 
I25.3 257 Aneurysm of heart 
31 
 
I25.4 271 Coronary artery aneurysm and dissection 
I25.5 480 Ischaemic cardiomyopathy 
I25.50 86 Ischaemic cardiomyopathy -- Reduced Left Ventricular Ejection Fraction (ISD 
Extension) 
I25.59 82 Ischaemic cardiomyopathy -- No information on Left Ventricular Ejection 
Fraction (ISD Extension) 
I25.6 34 Silent myocardial ischaemia 
I25.8 3251 Other forms of chronic ischaemic heart disease 
I25.9 7533
8 
Chronic ischaemic heart disease, unspecified 
I50.0 4326 Congestive heart failure 
I50.00 1688 Congestive heart failure -- Reduced Left Ventricular Ejection Fraction (ISD 
Extension) 
I50.01 494 Congestive heart failure -- Preserved Left Ventricular Ejection Fraction (ISD 
Extension) 
I50.09 5793 Congestive heart failure -- No information on Left Ventricular Ejection 
Fraction (ISD Extension) 
I50.1 1583
8 
Left ventricular failure 
I50.10 3501 Left ventricular failure -- Reduced Left Ventricular Ejection Fraction (ISD 
Extension) 
I50.11 496 Left ventricular failure -- Preserved Left Ventricular Ejection Fraction (ISD 
Extension) 
I50.19 3967 Left ventricular failure -- No information on Left Ventricular Ejection Fraction 
(ISD Extension) 
I50.9 3178 Heart failure, unspecified 
I50.90 1525 Heart failure, unspecified -- Reduced Left Ventricular Ejection Fraction (ISD 
Extension) 
I50.91 507 Heart failure, unspecified -- Preserved Left Ventricular Ejection Fraction (ISD 
Extension) 
I50.99 4104 Heart failure, unspecified -- No information on Left Ventricular Ejection 
Fraction (ISD Extension) 
I63.0 53 Cerebral infarction due to thrombosis of precerebral arteries 
I63.1 15 Cerebral infarction due to embolism of precerebral arteries 
I63.2 370 Cerebral infarction due to unspecified occlusion or stenosis of precerebral 
arteries 
I63.3 133 Cerebral infarction due to thrombosis of cerebral arteries 
I63.4 116 Cerebral infarction due to embolism of cerebral arteries 
I63.5 865 Cerebral infarction due to unspecified occlusion or stenosis of cerebral 
arteries 
I63.6 7 Cerebral infarction due to cerebral venous thrombosis, non-pyogenic 
I63.8 3319 Other cerebral infarction 
I63.9 1113
6 
Cerebral infarction, unspecified 
I64.0 8261 Stroke, not specified as haemorrhage or infarction 
I65.0 150 Occlusion and stenosis of vertebral artery 
I65.1 28 Occlusion and stenosis of basilar artery 
I65.2 4409 Occlusion and stenosis of carotid artery 
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I65.3 21 Occlusion and stenosis of multiple and bilateral precerebral arteries 
I65.8 16 Occlusion and stenosis of other precerebral artery 
I65.9 8 Occlusion and stenosis of unspecified precerebral artery 
I66.0 60 Occlusion and stenosis of middle cerebral artery 
I66.1 80 Occlusion and stenosis of anterior cerebral artery 
I66.2 77 Occlusion and stenosis of posterior cerebral artery 
I66.3 41 Occlusion and stenosis of cerebellar arteries 
I66.4 440 Occlusion and stenosis of multiple and bilateral cerebral arteries 
I66.8 10 Occlusion and stenosis of other cerebral artery 
I66.9 244 Occlusion and stenosis of unspecified cerebral artery 
I69.3 550 Sequelae of cerebral infarction 
I69.4 2754 Sequelae of stroke, not specified as haemorrhage or infarction 
I70.2 1501 Atherosclerosis of arteries of extremities 
I70.20 272 Atherosclerosis of arteries of extremities 
I70.21 167 Atherosclerosis of arteries of extremities 
I70.8 293 Atherosclerosis of other arteries 
I70.80 101 Atherosclerosis of other arteries 
I70.81 7 Atherosclerosis of other arteries 
I70.9 102 Generalized and unspecified atherosclerosis 
I70.90 55 Generalized and unspecified atherosclerosis 
I70.91 1 Generalized and unspecified atherosclerosis 
I73.9 2665
9 
Peripheral vascular disease, unspecified 
I79.2 894 Peripheral angiopathy in diseases classified elsewhere 
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Table S2 – Changes in risk classification and drug eligibility according to sensitivity analysis 
Sensitivity analysis Risk category N  Absolute 
change 
(N) 
Percentage 
age change 
from 
baseline 
Baseline analysis as 
described in manuscript 
(used as denominator 
throughout) 
Very high risk 188,367   
High risk 25,957   
Total eligiblea 80,830   
Moderate risk 
 
51,450   
Maximal ICD-Codes 
• I10-120 
(hypertensive 
disease and 
ischaemic heart 
disease) 
• I60-I66 (all 
cerebrovascular 
disease) 
• I70-I79 
(atherosclerosis, 
aortic and other 
aneurysms, PVD, 
arterial embolism 
and thrombosis and 
capillary diseases) 
 
Very high risk 197,233 8,866 4.71 
High risk 21,017 -4,940 -19.03 
Total eligiblea 82,994 2,164 2.68 
Moderate risk 47,524 -3,926 -7.63 
Microalbuminuria only 
 
Very high risk 175,092 -13,275 -7.05 
High risk 32,428 6,471 24.93 
Total eligiblea 77,521 -3,309 -4.09 
Moderate risk 
 
58,254 6,084 13.22 
Retinopathy, including 
background retinopathy 
(>R1) 
Very high risk 189,090 723 0.38 
High risk 25,478 -479 -1.85 
Total eligiblea 80,914 84 0.10 
Moderate risk 
 
51,206 -244 -0.47 
Age risk factor ≥60y Very high risk 198,141 9,774 5.19 
High risk 22,901 -3,056 -11.77 
Total eligiblea 84,729 3,899 4.82 
Moderate risk 
 
44,732 -6,718 -13.06 
Age risk factor ≥70y Very high risk 178,070 -10,297 -5.47 
High risk 29,643 3,686 14.20 
Total eligiblea 76,722 -4,108 -5.08 
Moderate risk 
 
58,061 6,611 12.85 
SBP ≥130mmHg Very high risk 192,315 3,948 2.10 
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High risk 25,257 -700 -2.70 
Total eligiblea 82,626 1,796 2.22 
Moderate risk 
 
48,202 -3,248 -6.31 
SBP ≥140mmHg Very high risk 185,618 -2,749 -1.46 
High risk 26,506 549 2.12 
Total eligiblea 79,558 -1,272 -1.57 
Moderate risk 
 
53,650 2,200 4.28 
LDL-C ≥2.0mmol/L Very high risk 194,027 5,660 3.00 
High risk 23,961 -1,996 -7.69 
Total eligiblea 83,009 2,179 2.70 
Moderate risk 
 
47,786 -3,664 -7.12 
LDL-C ≥3.0mmol/L Very high risk 187,164 -1,203 -0.64 
High risk 26,277 320 1.23 
Total eligiblea 80,294 -536 -0.66 
Moderate risk 
 
52,333 883 1.72 
TC ≥5.0mmol/L Very high risk 180,526 -7,841 -4.16 
High risk 28,353 2,396 9.23 
Total eligiblea 77,419 -3,411 -4.22 
Moderate risk 
 
56,895 5,455 10.58 
TC ≥4.0mmol/L Very high risk 200,716 12,349 6.56 
High risk 21,603 -4,354 -16.77 
Total eligiblea 85,624 4,794 5.93 
Moderate risk 
 
43,455 -7,996 -15.54 
Eligibility Thresholds b - excluding those with: 
 
HbA1c ≤48mmol/mol 
(≤6.5%) 
 
Total eligiblea 44,392 -38,602 
 
-45.08 
HbA1c ≤53mmol/mol 
(≤7%) 
 
Total eligiblea 27,159 -55,835 
 
-66.40 
HbA1c ≤58mmol/mol 
(≤7.5%) 
 
Total eligiblea 16,181 -66,813 
 
-79.98 
≥80y b Total eligiblea 63,739 -19,255 
 
-21.14 
≥85y  Total eligiblea 73,021 -9,973 
 
-9.66 
≥90y  Total eligiblea 78,350 -4,644 
 
-3.06 
a = Total eligible only includes those people who are drug-naïve or on metformin monotherapy. 
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b = characteristics not included in risk stratification criteria (hence risk categories not reported). 
People above/below specified cut off excluded (having previously been either drug-naïve or on 
metformin monotherapy and eligible).  
 
